

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4474678
<b>Application Number:</b>	10644579
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	5200
<b>Title of Invention:</b>	Use of enantiomeric pure escitalopram
<b>First Named Inventor/Applicant Name:</b>	Connie Sanchez
<b>Customer Number:</b>	07278
<b>Filer:</b>	Marie Louise Collazo/Judi Cordo
<b>Filer Authorized By:</b>	Marie Louise Collazo
<b>Attorney Docket Number:</b>	05432/100M919-US1
<b>Receipt Date:</b>	17-DEC-2008
<b>Filing Date:</b>	20-AUG-2003
<b>Time Stamp:</b>	15:42:33
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		IDS_for_filing.PDF	636600	yes	8
			acbb0bf721000fbc215c5f67245001861a1c3baf		

Multipart Description/PDF files in .zip description					
Document Description			Start	End	
Information Disclosure Statement Letter			1	4	
Information Disclosure Statement (IDS) Filed (5B/08)			5	8	
Warnings:					
Information:					
2	NPL Documents	NPL_Takeshi_Article.PDF	581100 c05c5085094f7a73b7b2cd4-97032d84a2975d4	no	7
Warnings:					
Information:					
3	NPL Documents	NPL_Hexal_Opposition.PDF	665055 425a7cdd4d7a3f1174966c6c48b09253d09c867	no	17
Warnings:					
Information:					
4	NPL Documents	NPL_Lepola_Effect_of_Citalopram_Article.PDF	366953 1417ca7f6cc5d2671d2c84c4a7c4e94343d829	no	5
Warnings:					
Information:					
5	NPL Documents	NPL_Lepola_Citalopram_in_Anxiety_Article.PDF	236636 b89c15e81211a27d6f57d3df43ed2156ccc0e41	no	3
Warnings:					
Information:					
6	NPL Documents	NPL_Ragneskog_Article.PDF	663169 60e5a557ba2f4c0bca74873807db852c8f66219	no	10
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
7	Foreign Reference	EP_0814084.PDF	1380060 8bcb7915a20c3f568b4d517be057915d2f72a86	no	26
Warnings:					
Information:					
8	Foreign Reference	WO_0112175.PDF	1599541 c3733705668408b5b20262dc1c58f1f5ad7d188	no	43
Warnings:					

Information:					
9	NPL Documents	NPL_Hogg_Article.PDF	119290 141982c3dac3941e313212412285d893979c2896	no	2
Warnings:					
Information:					
10	NPL Documents	NPL_Generics_Opposition.PDF	617942 25694e782464baf9f54db67b530707a229894f	no	17
Warnings:					
Information:					
11	NPL Documents	NPL_Gedeon_Opposition.PDF	505187 e7a8177a79732008d154b4d051504302c7b38e1	no	15
Warnings:					
Information:					
12	NPL Documents	NPL_Pilva_Opposition.PDF	653468 3c28e2944abab80542d81c5e7eff04b350c7c9b	no	20
Warnings:					
Information:					
13	NPL Documents	NPL_Teva_Opposition.PDF	736251 5e9f92fa667586a9d482703bdc43fb3bd730a116	no	19
Warnings:					
Information:					
14	NPL Documents	NPL_Forest_Article.PDF	166551 a0c23e14de53e9f9fc7f8ab870a114535a7a3cc	no	3
Warnings:					
Information:					
15	NPL Documents	NPL_Noble_Article.PDF	1594373 55ad9974b0ffce7052642d916582cd8591adec84	no	22
Warnings:					
Information:					
16	NPL Documents	NPL_Baumann_Article.PDF	697157 251339cc88e45d0c9938be794c4604e155720d41	no	9
Warnings:					
Information:					
17	Foreign Reference	WO_9913877.PDF	2820490 4cc173032c0805c384db441cd85dc370a091e7fb	no	75
Warnings:					

<b>Information:</b>					
18	NPL Documents	NPL_Emanuel_Article.PDF	59540 #f9c0cb152b7b6c7fa1b5d8b154fc3b03e7e1d6e	no	1
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	NPL_Parker_Article.PDF	647574 f3b4e6c37ab02a189493812ca001219b972e793f	no	8
<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	NPL_Laux_Article.pdf	70714 f79ca0ab5d5444b0c21e1746a01c292b7cc1ce9	no	5
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	NPL_Egis_Opposition.pdf	1319773 3d004736a1744e0a563887abfdca48c66c58e5	no	31
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	NPL_Connor_Article.PDF	757270 d8ff13ca8bc1788c734b8d9195d93db0e0592bb	no	9
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	NPL_Uhlenhuth_Article.PDF	780877 9e62362e49e45169a71f6fbb1825e8b26fd1e02	no	10
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	NPL_Fachinformation_Cipralext_10mg_20mg.PDF	1175139 7a275aed14300190b0da36202a8c0f1c617217c	no	10
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	NPL_FDA's_Policy_Statement.PDF	396488 b38c8e2e0b0b960697f713e28f7723c417391b077	no	6
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	NPL_Cipramil_20_mg_40_mg.PDF	596574 a201292846748b1b79c0285c4bb6053c67b1d5	no	5
<b>Warnings:</b>					

Information:					
27	NPL Documents	NPL_Lydiard_Article.PDF	958330 b811986c3a57472964e4d2899c138a5d2d0d4	no	9
Warnings:					
Information:					
28	NPL Documents	NPL_Brawman_Article.PDF	333567 66ac2369479c9c6359a2c5d93b3a3c2587c84173	no	3
Warnings:					
Information:					
29	NPL Documents	NPL_Rocca_Article.PDF	558452 186af9512e53a5e0b19f41600721874727e152	no	7
Warnings:					
Information:					
30	NPL Documents	NPL_Silverstone_Article.PDF	870289 4d98e9629761d4d2d4481164b2456192b3a8	no	8
Warnings:					
Information:					
31	NPL Documents	NPL_Hashimoto_Effects_of_the_Coadministration_Article.PDF	373283 ec918dbffcd9476c3d6c1da5f815e14b79e71	no	5
Warnings:					
Information:					
32	NPL Documents	NPL_Lundbeck_Annual_Report_1999.PDF	404079 9bc52ba0f9f7060a97314e994c1f52a88a0478af	no	3
Warnings:					
Information:					
33	NPL Documents	NPL_Cutler_Article.PDF	786091 3037a26a03c487aa12d999a080a0d71c51e929	no	9
Warnings:					
Information:					
34	NPL Documents	NPL_Culpepper_Article.PDF	516011 e8f1187c955ef102db4a6067af6d4940a5e1	no	6
Warnings:					
Information:					
35	NPL Documents	NPL_Lundbeck_Annual_Report_1998.PDF	550650 4c66b81cf7e4b4e92418108506492dc71d5c1a0	no	3
Warnings:					

Information:					
36	NPL Documents	NPL_Rote_Liste.PDF	220710 0a786ac3d91ec2792ae6935412537b447056a3841	no	3
Warnings:					
Information:					
37	NPL Documents	NPL_Maier_Article.PDF	55747 2119c9288b1d463f22365c386c9181c88b1c777c6	no	2
Warnings:					
Information:					
38	NPL Documents	NPL_Bondolfi_Article.PDF	612215 79caad67d98786c01b1e72cc96518e9f0926	no	5
Warnings:					
Information:					
39	NPL Documents	NPL_Hashimoto_Effects_of_Conditioned_Article.PDF	698556 230207606ebcb99fb027d447b7b1a0515614372	no	8
Warnings:					
Information:					
40	NPL Documents	NPL_Sidhu_Article.PDF	536814 a4d81d9e37d69b30e23576b28cc8c6de9a8fc	no	7
Warnings:					
Information:					
41	NPL Documents	NPL_Hutt_Article.PDF	772646 66906687391160c02ab45f42129778670428a11	no	12
Warnings:					
Information:					
42	NPL Documents	NPL_Kose_Article.PDF	244003 0031aa2ef129d355a5a23f0b5926cc98f99fab6	no	5
Warnings:					
Information:					
43	NPL Documents	NPL_Hashimoto_Serotonin_Article.PDF	461345 854fd1c529436d46d4d11341cd89012c053667e	no	5
Warnings:					
Information:					
44	NPL Documents	NPL_Richels_Article.PDF	1185723 333820d299b3192a4664bdc01b1d75ac53c32c	no	12
Warnings:					

<b>Information:</b>					
45	NPL Documents	NPL_Lhuillier_Article.PDF	182134 8345e6508des26b2746a8b011ab0132c8a2	no	4
<b>Warnings:</b>					
<b>Information:</b>					
46	NPL Documents	NPL_Boerner_Article.PDF	923775 02/81323438b5ba0b79f9ba9d13ac5ef5a88	no	8
<b>Warnings:</b>					
<b>Information:</b>					
47	NPL Documents	NPL_Rochat_Article.PDF	572981 7ab18dc9c279d98e6c260fba027c18c36cf1ce	no	8
<b>Warnings:</b>					
<b>Information:</b>					
48	NPL Documents	NPL_NZ_Examination_Report.PDF	83998 44bba01161675ed788f6c55e55cd402de0b0	no	3
<b>Warnings:</b>					
<b>Information:</b>					
49	NPL Documents	NPL_Sorbera_Article.PDF	510054 a5f587bc9c766818c3b378873ebaf72e713d7	no	6
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			32255225		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>          If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					